{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:03:40Z","timestamp":1786993420307,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jsbmb.2024.106636","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T13:50:44Z","timestamp":1731419444000},"page":"106636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A study of the role of androgen receptor and androgen receptor variant 7 in TNBC patients and the effect of their targeting by Enzalutamide and EPI-001 in MDA-MB-231"],"prefix":"10.1016","volume":"245","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-7371","authenticated-orcid":false,"given":"Belal M.","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8819-9891","authenticated-orcid":false,"given":"Hanan S.","family":"El-Abhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5831-4083","authenticated-orcid":false,"given":"Ghada","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan R.","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Aliedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7894-3514","authenticated-orcid":false,"given":"Marwa","family":"Sharaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2883-8775","authenticated-orcid":false,"given":"Samia A.","family":"Shouman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1372-8554","authenticated-orcid":false,"given":"Marwa","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jsbmb.2024.106636_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.32604\/or.2023.028525","article-title":"Targeting triple-negative breast cancer: a clinical perspective","volume":"31","author":"Popovic","year":"2023","journal-title":"Oncol. Res."},{"issue":"42","key":"10.1016\/j.jsbmb.2024.106636_bib2","doi-asserted-by":"crossref","first-page":"44728","DOI":"10.18632\/oncotarget.6296","article-title":"Expression of androgen receptor splice variants in clinical breast cancers","volume":"6","author":"Hickey","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jsbmb.2024.106636_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.21037\/tbcr-23-44","article-title":"Androgen receptor in breast cancer and its clinical implication","volume":"4","author":"Hackbart","year":"2023","journal-title":"Transl. Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.jsbmb.2024.106636_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1530\/ERC-16-0068","article-title":"Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells","volume":"23","author":"Caiazza","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"issue":"15","key":"10.1016\/j.jsbmb.2024.106636_bib5","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-16-2339","article-title":"A Phase I\/Ib study of enzalutamide alone and in combination with endocrine therapies in women with advanced breast cancer","volume":"23","author":"Schwartzberg","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.jsbmb.2024.106636_bib6","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.3390\/cancers14194877","article-title":"The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer","volume":"14","author":"Zheng","year":"2022","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.jsbmb.2024.106636_bib7","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1111\/jcmm.15831","article-title":"The AKR1C3\/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression","volume":"24","author":"Wang","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"17","key":"10.1016\/j.jsbmb.2024.106636_bib8","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1158\/1078-0432.CCR-15-2901","article-title":"Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer","volume":"22","author":"Yang","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106636_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12032-023-02259-4","article-title":"Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors","volume":"41","author":"Akrida","year":"2023","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106636_bib10","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1038\/s41467-021-26502-6","article-title":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","volume":"12","author":"Lehmann","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106636_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12864-018-4775-x","article-title":"TSVdb: a web-tool for TCGA splicing variants analysis","volume":"19","author":"Sun","year":"2018","journal-title":"BMC Genom."},{"issue":"6","key":"10.1016\/j.jsbmb.2024.106636_bib12","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.18632\/oncotarget.2924","article-title":"EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer","volume":"6","author":"Brand","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106636_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3599","article-title":"Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide","volume":"16","author":"Cochrane","year":"2014","journal-title":"Breast Cancer Res."},{"issue":"12","key":"10.1016\/j.jsbmb.2024.106636_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051862","article-title":"Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization","volume":"7","author":"Budczies","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106636_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21608\/resoncol.2019.11625.1076","article-title":"Clinicopathological characteristics and survival of triple-negative breast cancer patients: a single Institution Study from Egypt","volume":"15","author":"Makar","year":"2019","journal-title":"J. Res. Oncol."},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106636_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7150\/jca.10944","article-title":"Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer","volume":"7","author":"Qiu","year":"2016","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106636_bib17","first-page":"9","article-title":"Core promoter in TNBC is highly mutated with rich ethnic signature","volume":"7","author":"Huang","year":"2023","journal-title":"Brief\u00a0Funct. Genom."},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106636_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10549-022-06736-8","article-title":"Are there differences in outcomes by race among women with metastatic triple-negative breast cancer?","volume":"196","author":"Oppong","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106636_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CBC.2009.n.005","article-title":"Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design","volume":"9","author":"Kassam","year":"2009","journal-title":"Clin. Breast Cancer"},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106636_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3892\/mco.2013.230","article-title":"Clinical characteristics and prognostic analysis of triple-negative breast cancer patients","volume":"2","author":"Yuan","year":"2014","journal-title":"Mol. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jsbmb.2024.106636_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3892\/mco.2021.2261","article-title":"Strong impact of pathological node-negative on long-term overall survival of patients with triple-negative breast cancer receiving neoadjuvant chemotherapy","volume":"14","author":"Nogi","year":"2021","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2024.106636_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/1179554918790563","article-title":"Survival study of triple-negative and non-triple-negative breast cancer in a brazilian cohort","volume":"12","author":"Goncalves","year":"2018","journal-title":"Clin. Med. Insights Oncol."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106636_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2741\/s527","article-title":"The persisting puzzle of racial disparity in triple negative breast cancer: looking through a new lens","volume":"11","author":"Garlapati","year":"2019","journal-title":"Front. Biosci. (Sch. Ed.)"},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106636_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41416-018-0142-6","article-title":"Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers","volume":"119","author":"Guiu","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.jsbmb.2024.106636_bib25","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1158\/1078-0432.CCR-17-1199","article-title":"The magnitude of androgen receptor positivity in breast cancer is critical for reliable prediction of disease outcome","volume":"24","author":"Ricciardelli","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jsbmb.2024.106636_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197827","article-title":"Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features","volume":"13","author":"Astvatsaturyan","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jsbmb.2024.106636_bib27","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djy173","article-title":"Androgen receptor expression and breast cancer survival: results from the nurses' health studies","volume":"111","author":"Kensler","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.jsbmb.2024.106636_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070995","article-title":"Prognostic role of androgen receptor in triple negative breast cancer: a multi-institutional study","volume":"11","author":"Bhattarai","year":"2019","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.jsbmb.2024.106636_bib29","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1158\/0008-5472.CAN-09-0452","article-title":"Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer","volume":"69","author":"Peters","year":"2009","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.jsbmb.2024.106636_bib30","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/modpathol.2011.54","article-title":"Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study","volume":"24","author":"Collins","year":"2011","journal-title":"Mod. Pathol."},{"issue":"9","key":"10.1016\/j.jsbmb.2024.106636_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092639","article-title":"Expression of AR-V7 (Androgen Receptor Variant 7) protein in granular cytoplasmic structures is an independent prognostic factor in prostate cancer patients","volume":"12","author":"Konig","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106636_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12672-014-0171-4","article-title":"Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues","volume":"5","author":"Hu","year":"2014","journal-title":"Horm. Cancer"},{"key":"10.1016\/j.jsbmb.2024.106636_bib33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fendo.2018.00492","article-title":"The androgen receptor in breast cancer","volume":"9","author":"Giovannelli","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.jsbmb.2024.106636_bib34","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41379-021-00924-5","article-title":"Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations","volume":"35","author":"Ferguson","year":"2022","journal-title":"Mod. Pathol."},{"issue":"20","key":"10.1016\/j.jsbmb.2024.106636_bib35","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1158\/0008-5472.CAN-11-2373","article-title":"ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion","volume":"72","author":"Vigil","year":"2012","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.jsbmb.2024.106636_bib36","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1210\/me.2009-0472","article-title":"Androgens induce nongenomic stimulation of colonic contractile activity through induction of calcium sensitization and phosphorylation of LC20 and CPI-17","volume":"24","author":"Gonzalez-Montelongo","year":"2010","journal-title":"Mol. Endocrinol."},{"issue":"5","key":"10.1016\/j.jsbmb.2024.106636_bib37","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1210\/me.2011-1130","article-title":"RhoA as a mediator of clinically relevant androgen action in prostate cancer cells","volume":"26","author":"Schmidt","year":"2012","journal-title":"Mol. Endocrinol."},{"issue":"2","key":"10.1016\/j.jsbmb.2024.106636_bib38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/pros.22901","article-title":"Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes","volume":"75","author":"Kong","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.jsbmb.2024.106636_bib39","article-title":"Mechanical stretch promotes macrophage polarization and inflammation via the RhoA-ROCK\/NF-kappaB pathway","volume":"2022","author":"Tu","year":"2022","journal-title":"BioMed\u00a0Res. Int."},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106636_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s10020-023-00734-2","article-title":"Mechanism of RhoA regulating benign prostatic hyperplasia: RhoA-ROCK-beta-catenin signaling axis and static & dynamic dual roles","volume":"29","author":"Shan","year":"2023","journal-title":"Mol. Med."},{"issue":"12","key":"10.1016\/j.jsbmb.2024.106636_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202300399","article-title":"Triptolide reduces MDA-MB-231 cell metastasis by attenuating epithelial-mesenchymal transition through the ROCK\/PTEN\/Akt axis","volume":"20","author":"Wu","year":"2023","journal-title":"Chem. Biodivers."},{"issue":"25","key":"10.1016\/j.jsbmb.2024.106636_bib42","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1038\/s41388-019-0768-8","article-title":"A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer","volume":"38","author":"Bai","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jsbmb.2024.106636_bib43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41389-023-00449-3","article-title":"Androgen receptor variant 7 exacerbates hepatocarcinogenesis in a c-MYC-driven mouse HCC model","volume":"12","author":"Kido","year":"2023","journal-title":"Oncogenesis"},{"key":"10.1016\/j.jsbmb.2024.106636_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101761","article-title":"An androgen receptor regulated gene score is associated with epithelial to mesenchymal transition features in triple negative breast cancers","volume":"37","author":"Rajarajan","year":"2023","journal-title":"Transl. Oncol."},{"issue":"5","key":"10.1016\/j.jsbmb.2024.106636_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063466","article-title":"Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells","volume":"8","author":"Cottard","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jsbmb.2024.106636_bib46","first-page":"617","article-title":"Enzalutamide and EPI-001 modulate cell proliferation and metastasis markers in T47D by targeting AR\/ARV7","volume":"34","author":"Ali","year":"2023","journal-title":"Indones. J. Pharm."},{"key":"10.1016\/j.jsbmb.2024.106636_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109320","article-title":"Aberrant N-cadherin expression in cancer","volume":"118","author":"Cao","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.jsbmb.2024.106636_bib48","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3390\/ijms25031817","article-title":"Treatments targeting the androgen receptor and its splice variants in breast cancer","volume":"25","author":"Tien","year":"2024","journal-title":"Int. J. Mol. Sci."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076024001845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076024001845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T17:06:29Z","timestamp":1732813589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076024001845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":48,"alternative-id":["S0960076024001845"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2024.106636","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A study of the role of androgen receptor and androgen receptor variant 7 in TNBC patients and the effect of their targeting by Enzalutamide and EPI-001 in MDA-MB-231","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2024.106636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106636"}}